NCT01691872撤回1 期
An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- AUC0-∞ of retigabine
研究概览
简要总结
This is an open-label, single centre, parallel group study to evaluate the safety and pharmacokinetics of single oral doses of retigabine XR formulation in healthy adult Japanese subjects. To compare the pharmacokinetic and safety profile, Caucasian subjects are also incorporated. This study is intended to facilitate inclusion of Japanese patients in the global phase III program for retigabine XR formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male subject between 20 and 45 years of age inclusive, at the time of signing the informed consent.
- •Japanese ancestry defined as being born in Japan, having four ethnic Japanese grandparents, holding a Japanese passport or identity papers and being able to speak Japanese. OR Caucasian defined as an individual having four grandparents who are all descendents of the original people of Europe.
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and 12-lead ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Body weight ≥ 50 kg and BMI within the range 18.5 - 24.9 kg/m2 (inclusive).
- •Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed separately. This criterion must be followed from the time of the first dose of study medication until 1 week post-last dose
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •Single QTcB or QTcF< 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
排除标准
- •Subject has made a suicide attempt in the past or, in the investigator's judgment, poses a significant suicide risk. Evidence of serious suicide risk may include any history of suicidal behavior in the past 6 months and/or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
- •A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody or HIV antigen/antibody result within 3 months of screening
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive pre-study drug/alcohol screen.
- •History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 360 ml of beer, 150 ml of table wine or 45 ml of 80 proof distilled spirits.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 day period.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
- •History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- •Unable to refrain from consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
研究组 & 干预措施
Japanese
Experimental
Retigabine 300mg single-dose
干预措施: Retigabine (Drug)
Caucasian
Experimental
Retigabine 300mg single-dose
干预措施: Retigabine (Drug)
结局指标
主要结局
AUC0-∞ of retigabine
时间窗: up to 96h post dose
Area under the concentration-time curve from pre-dose to last time of quantifiable concentration of retigabine
Adverse Events
时间窗: up to 96h post dose
Number of participants with adverse events as a measure of safety and tolerability (evaluated by the result of Clinical safety laboratory tests, vital signs, 12-lead ECG, telemetry and clinical monitoring/observation
Cmax of retigabine
时间窗: up to 96h post dose
Maximum observed concentration of retigabine
Tmax of retigabine
时间窗: up to 96h post dose
Time of occurance of Cmax of retigabine
t1/2 of retigabine
时间窗: up to 96h post dose
Terminal phase half-life of retigabine
次要结局
- t1/2 of NAMR(up to 96h post dose)
- Tmax of NAMR(up to 96h post dose)
- fe(up to 96h post dose)
- CLr(up to 96h post dose)
- AUC0-∞ of NAMR(up to 96h post dose)
- Cmax of NAMR(up to 96h post dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic FunctionMild and Moderate Hepatic ImpairmentNCT04116476Mitsubishi Tanabe Pharma America Inc.23
已完成
1 期
A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838Healthy VolunteerNCT01510899Hoffmann-La Roche12
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver DamageHealthy VolunteerNCT02300025Genentech, Inc.28
已完成
1 期
A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)Renal ImpairmentNCT03159416The Medicines Company31
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female SubjectsContraceptionNCT05677035Hyundai Pharm20